Opinion|Videos|October 21, 2024
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Key Takeaways
- CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety.
- Routes of administration vary, with some trials using intravenous delivery and others exploring intravesical administration to optimize therapeutic outcomes.
Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, KEYNOTE, and ALBAN, detailing how routes of administration and durations of therapy vary among these agents and emphasizing the significance of differences in control arms within the trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you explain in detail which PD-1/PD-L1 inhibitors are being investigated in phase 3 trials for BCG-naive patients? [describe CREST, POTOMAC, KEYNOTE, ALBAN,] (PMID 38849286; DOI
10.1016/S0302-2838(24)01302-2 ) - How do the routes of administration and durations of therapy differ among the agents/trials?
Bedke 2023 Steinberg 2024
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5